Drug intelligence / Profile preview

Neurapas balance

Development stage
Phase 1
Lead developer
Pascoe Naturmedizin
Administration
Oral
01

Overview

Neurapas balance is a herbal medicinal product developed and manufactured by Pascoe Pharmazeutische Praeparate GmbH. It is a fixed-dose combination of three standardized plant extracts: *Hypericum perforatum* (St. John's Wort), *Passiflora incarnata* (Passionflower), and *Valeriana officinalis* (Valerian). The product is indicated for the treatment of mild to moderate depressive episodes accompanied by anxiety, nervous restlessness, and sleep disturbances. Its therapeutic effect is derived from the synergistic action of its components: St. John's Wort acts as a multi-reuptake inhibitor of serotonin, norepinephrine, and dopamine; Passionflower provides anxiolytic properties through GABAergic modulation; and Valerian serves as a mild sedative. Clinical trials have utilized quantitative EEG to demonstrate its pharmacological effects on brain activity, confirming its impact on central nervous system function.

Brand names
Neurapas balance
Other names
hypericum + passionflower + valerianSt. John’s Wort + passionflower + valerianHypericum perforatum + Passiflora incarnata + Valeriana officinalis
02

Targets

SERT (Sodium-dependent serotonin transporter)GABRR (GABA-A receptor subunit rho)HTR2C (5-hydroxytryptamine 2C receptor)MTNR1A (MT1)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Neurapas balance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurapas balance.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call